Mutated P53 is another potential biomarker and therapeutic target for people with breast cancer, with a number of pharmaceuticals on the market that can restore the wild-type features of mutant P53 proteins with demonstrated anti-cancer efficacy [54, 55]. The gene discussed is TP53; the disease is cancer.